Symptom-centric view

Tooth loss

Substances reporting Tooth loss disproportionately — ranked by ROR.

Pain Drug ineffective Off label use Fatigue Dyspnoea Acute kidney injury

showing 20 of 20

Substance ↓	ROR [95% CI]	Reports	Category	Label
tenofovir disoproxil fumarate —	310.6 [301.8–319.6]	9,822	algemeen	new
tenofovir alafenamide —	296.5 [287.5–305.8]	6,892	algemeen	new
rilpivirine hydrochloride —	268.3 [256.0–281.1]	2,396	algemeen	new
rilpivirine —	123.6 [118.3–129.3]	2,402	algemeen	new
emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate —	464.8 [440.2–490.7]	1,992	algemeen	new
emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide —	309.1 [285.5–334.7]	814	algemeen	new
emtricitabine and tenofovir disoproxil fumarate —	382.2 [371.2–393.6]	8,779	algemeen	new
emtricitabine and tenofovir alafenamide —	320.1 [310.0–330.4]	6,383	algemeen	new
emtricitabine —	299.4 [291.0–308.0]	10,205	algemeen	new
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate —	429.8 [409.4–451.3]	2,465	algemeen	new
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide —	327.3 [311.6–343.8]	2,256	algemeen	new
dolutegravir sodium and rilpivirine hydrochloride —	15.2 [10.3–22.4]	26	algemeen	new
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide —	266.2 [242.2–292.5]	556	algemeen	new
darunavir ethanolate and cobicistat —	28.2 [21.1–37.5]	48	algemeen	new
darunavir —	37.8 [34.9–40.8]	672	algemeen	new
cobicistat —	313.5 [302.1–325.5]	4,160	algemeen	new
buprenorphine hydrochloride and naloxone hydrochloride —	14.8 [10.5–20.9]	33	algemeen	new
buprenorphine and naloxone —	20.7 [13.8–31.0]	24	algemeen	new
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate —	284.0 [272.8–295.7]	3,396	algemeen	new
abacavir sulfate, dolutegravir sodium, lamivudine —	14.0 [11.3–17.3]	87	algemeen	new

ROR = reporting odds ratio vs. the full FAERS corpus. A signal is not a cause. Source: openFDA (FAERS).